Proteostasis Therapeutics Inc (PTI)

10.24
0.12 1.16
NASDAQ : Health Care
Prev Close 10.36
Open 10.13
Day Low/High 10.05 / 10.57
52 Wk Low/High 5.27 / 20.47
Volume 45.07K
Avg Volume 59.20K
Exchange NASDAQ
Shares Outstanding 19.14M
Market Cap 208.24M
Div & Yield N.A. (N.A)

Latest News

Proteostasis Therapeutics, Inc. Presents New Data Demonstrating Potential For Genotype-Agnostic And Combination Therapies For People With Cystic Fibrosis

Proteostasis Therapeutics, Inc. Presents New Data Demonstrating Potential For Genotype-Agnostic And Combination Therapies For People With Cystic Fibrosis

Data Presented at 13th Annual ECFS Basic Science Conference on Novel Therapies Targeting Cystic Fibrosis

Proteostasis Therapeutics, Inc. Announces Scientific Presentations At 13th Annual European Cystic Fibrosis Society Basic Science Conference

Proteostasis Therapeutics, Inc. Announces Scientific Presentations At 13th Annual European Cystic Fibrosis Society Basic Science Conference

Company to Hold Investor Conference Call and Webcast to Outline Scientific and Corporate Updates on March 30, 2016

Patheon Completes Plan Of Arrangement

Patheon Completes Plan Of Arrangement

JLL/Delta Dutch Newco B.V. Announces Offering Of $500 Million Senior Notes Due 2022

JLL/Delta Dutch Newco B.V. Announces Offering Of $500 Million Senior Notes Due 2022

Offering will finance in part acquisition of Patheon Inc. and DPP Pharmaceuticals Business of DSM

Royal DSM And JLL Create Leading Pharma Services Company In USD 2.6 Bn Transaction

Royal DSM And JLL Create Leading Pharma Services Company In USD 2.6 Bn Transaction

Global CDMO company combines DSM Pharmaceutical Products and Patheon

Royal DSM And JLL Create Leading Pharma Services Company In USD 2.6 Bn Transaction

Royal DSM And JLL Create Leading Pharma Services Company In USD 2.6 Bn Transaction

JLL Partners (“JLL”), a leading middle-market private equity firm, and Royal DSM, the global Life Sciences and Materials Sciences company, today announced the creation of a new company, which will be a leading ...